Concord Medical Services Holdings Limited
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Jianyu Yang
- Full Time Employees
- 595
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Tower A, Global Trade Center Beijing People's Republic of China 100013
- IPO Date
- Dec 11, 2009
- CIK
- 0001472072
- Website
- concordmedical.com
- Similar Companies
- Business
- Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services include linear accelerators external beam radiotherapy, gamma knife radiosurgery, head gamma knife systems, body gamma knife systems, and diagnostic imaging services. The company's other treatments and diagnostic services comprise computed tomography scanners. In addition, it provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, the company offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, it operates specialty cancer hospitals, which offer radiotherapy services, diagnostic imaging services, chemotherapy, and surgery. As of December 31, 2021, it operated a network of 16 cooperative centers based in 13 hospitals. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
Company News
Concord Healthcare Announces Completion of China's First Proton Therapy for Choroidal Malignant Melanoma
Concord Healthcare Announces Official Release of the Proton Therapy Large Model
Concord Medical Files Annual Report on Form 20-F for Fiscal 2024
Concord Medical Announces Result of 2024 Annual General Meeting
Concord Healthcare Announces Approval Granted to the Application for the Proton Therapy Equipment Registration Certificate
Concord Medical Schedules 2024 Annual Meeting of Shareholders
Concord Medical Reports Financial Results for the First Half of 2024
Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
Concord Medical Regains Compliance with NYSE Minimum Price Requirement
CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE
Canagold Resources Ltd. Announces Voting Results From Annual General Meeting
Canagold Initiates Resource Expansion Drilling at New Polaris Project
Concord Medical Files 2023 Annual Report on Form 20-F
Canagold Resources Ltd. Announces Closing of $4.1M Charity Flow Through Financing
Concord Medical Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price
Concord Medical Announces Listing of Its Subsidiary on The Stock Exchange of Hong Kong Limited
Canagold Appoints Chris Pharness as Senior Vice President Sustainability and Permitting
Concord Medical Schedules 2023 Annual Meeting of Shareholders
Concord Medical Reports Financial Results for the First Half of 2023